ARCT - Arcturus' mRNA therapy for cystic fibrosis cleared for early-stage trial in New Zealand

• Arcturus Therapeutics ( NASDAQ: ARCT ) said its clinical trial application (CTA) seeking to start a phase 1 study of inhaled mRNA medicine ARCT-032 to treat cystic fibrosis (CF), received approval in New Zealand.
• CF is an inherited disorder which damages the lungs, digestive system and other organs. The disorder affects the cells producing mucus, sweat and digestive juices and a defective gene makes them thick causing them to block tubes and passageways.
• "We believe the advantages driven by our proprietary LUNAR delivery technology, advanced mRNA purification processes, and manufacturing know-how may allow ARCT-032 to restore healthy CFTR protein in the lungs of people with CF, including those that currently do not have effective treatment options," said Arcturus President and CEO Joseph Payne.
• The company noted that ARCT-032 will use its LUNAR lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs.

For further details see: